Nestin

Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Retrieved on: 
Wednesday, October 18, 2023
Principal, Survival, Standard of care, Trial of the century, Harvard Medical School, Manuscript, Break, CADL, MD, Doctor of Philosophy, HGG, Disease, Nestin, Clinical trial, Immune system, Antibody, SOC, Tumor microenvironment, Therapy, Patient, Hospital, Glioblastoma, Toxicity, Seroconversion, Pharmaceutical industry, Vaccine, Medical imaging, Candel, Fellow of the Academy of Medical Sciences, Brigham, Nature

The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here .

Key Points: 
  • The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here .
  • Importantly, CAN-3110 treatment was associated with a significant increase in immune cells in the tumor microenvironment and in the peripheral blood.
  • Of importance, patients with recurrent HGG who had pre-existing antibodies to HSV-1 virus (66% of the patients) had a median overall survival of 14.2 months.
  • Accordingly, we observed increased diversity of the T-cell receptor repertoire after a single injection of CAN-3110 in recurrent HGG patients.

Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, August 10, 2023
Injection, Insurance, Gene, Survival, Clinical trial, Nestin, NSCLC, SOC, Lung cancer, American Society of Gene and Cell Therapy, Pharmacist, ASCO, Development, American Society of Clinical Oncology, MD, Patient, Standard of care, Administration, HGG, Annual general meeting, Cell, Research, MOS, Break, Therapy, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Video game, Candel, Doctor of Philosophy, Fellow of the Academy of Medical Sciences, Q4

NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Points: 
  • NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
  • Research and Development Expenses: Research and development expenses were $5.9 million for the second quarter of 2023 compared to $5.0 million for the second quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $3.6 million for the second quarter of 2023 compared to $3.8 million for the second quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the second quarter of 2023 and the second quarter of 2022.

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Retrieved on: 
Friday, May 19, 2023
HSV, Survival rate, Injection, Arm, Histology, Gene, Neoplasm, Survival, Clinical trial, Cyclophosphamide, Nestin, SOC, Doctor of Philosophy, HIV disease progression rates, MD, Patient, Standard of care, Cell, MOS, Therapy, CADL, Society, Safety, Pharmaceutical industry, Vaccine, Candel, Fellow of the Academy of Medical Sciences

The data were presented today in an Oral Presentation Session at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

Key Points: 
  • The data were presented today in an Oral Presentation Session at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
  • “We are encouraged by the increased survival of treated patients in two independent cohorts observed to date.
  • mOS in arm B is ongoing at 12.0 months and supports the encouraging clinical activity of CAN-3110 observed in in arm A.
  • Additional extensive biomarker studies including histology, transcriptomics, and single cell sequencing are ongoing.

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 30, 2023
HSV, Pancreatic cancer, Insurance, Herpes simplex virus, University, Partnership, ICI, Survival, Clinical trial, Silicon Valley Bank, Immunotherapy, Nestin, Toxicity, Brain, NSCLC, Lung cancer, Doctor of Philosophy, TWELVE, Rated R, MS, University of Pennsylvania, Silicon, Development, HIV disease progression rates, Patient, Standard of care, Content discovery platform, Administration, HGG, Biology, PD-1, Research, Therapy, CADL, Tumor microenvironment, PD-L1, Valaciclovir, Nivolumab, Prostate cancer, Enlightenment, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency, Society, Candel, SOC, Cancer, Fellow of the Academy of Medical Sciences, MD

In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.

Key Points: 
  • In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.
  • Importantly, CAN-2409 demonstrated a favorable change in the trajectory of tumor growth in all patients for whom pre-enrollment scans were available.
  • The Company is encouraged by the results and plans to present additional data in Q3 2023.
  • Research and Development Expenses: Research and development expenses were $5.0 million for the fourth quarter of 2022 compared to $3.9 million for the fourth quarter of 2021, and $20.8 million for the full-year 2022 compared to $15.2 million for the full-year 2021.

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

Retrieved on: 
Friday, November 18, 2022
Doctor of Philosophy, Immunogenic cell death, Glioblastoma, Therapy, Brain, Patient, Virulence, Data, Society, Neoplasm, Tumor microenvironment, Injection, SNO, Disease, MD, HSV, CADL, Nestin, Cancer, Form, Pakistan Society of Neuro-Oncology, Content discovery platform, Clinical trial, Survival, Biology, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences, Candel

An overview of this data will be presented in-person at the Society for Neuro-Oncology (SNO) 27th Annual Meeting today starting at 5:30 pm ET in Tampa, Florida.

Key Points: 
  • An overview of this data will be presented in-person at the Society for Neuro-Oncology (SNO) 27th Annual Meeting today starting at 5:30 pm ET in Tampa, Florida.
  • Data will be reported from 41 patients who were administered CAN-3110, with 40 patients having received a single injection and one patient having received two injections.
  • Diversity of the T cell receptor repertoire after CAN-3110 administration was reported to be associated with overall survival.
  • The effects of multiple doses of CAN-3110 in recurrent glioblastoma are currently being evaluated in an ongoing phase 1 clinical trial.

Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

Retrieved on: 
Friday, November 12, 2021
Society, Population, SITC, Cancer, Private Securities Litigation Reform Act, Therapy, ICP34.5, MD, Chemokine, Neoplasm, Cytokine, Immunogenic cell death, HSV, Doctor of Philosophy, CADL, Trial of the century, Tumor microenvironment, American Society of Clinical Oncology, Histology, Annual general meeting, Company, GLOBE, Mace Head Atmospheric Research Station, Immunology, SEC, ASCO, Nestin, Survival, Nasdaq, Patient, HGG, Adult, Vaccine, Pharmaceutical industry

During the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2021, Candel reported preliminary clinical data demonstrating an overall survival of 11.7 months in this difficult-to-treat patient population.

Key Points: 
  • During the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2021, Candel reported preliminary clinical data demonstrating an overall survival of 11.7 months in this difficult-to-treat patient population.
  • These findings collectively indicate that CAN-3110 treatment can induce both local and systemic immune activation associated with an encouraging clinical response.
  • There is a critical need for treatment options for patients with recurrent high-grade glioma.
  • Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics to Participate in Three Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 2, 2021
Nestin, Pancreatic cancer, MD, Cancer, Neoplasm, Patient, Private Securities Litigation Reform Act, Large-cell lung carcinoma, SEC, HSV, Adult, Company, Herpes simplex virus, Trial of the century, CADL, Immunogenic cell death, Nasdaq, Therapy, ICP34.5, Tumor microenvironment, Combination therapy, GLOBE, Doctor of Philosophy, CD8, Form, Pharmaceutical industry, Online shopping, Vaccine

At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment.

Key Points: 
  • At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment.
  • Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors.
  • Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies.
  • Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies

Retrieved on: 
Monday, November 1, 2021
Nestin, Pancreatic cancer, MD, Human, Cancer, Oncolytic virus, Neoplasm, Glioblastoma, Patient, Private Securities Litigation Reform Act, Large-cell lung carcinoma, Society, Clinical trial, SNO, SEC, HSV, Conference, Adult, Company, Herpes simplex virus, Trial of the century, CADL, Immunogenic cell death, Nasdaq, Therapy, ICP34.5, Tumor microenvironment, Combination therapy, GLOBE, CD8, Form, Pharmaceutical industry, Vaccine

NEEDHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced its participation in upcoming medical and scientific conferences.

Key Points: 
  • NEEDHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced its participation in upcoming medical and scientific conferences.
  • Candel President and Chief Executive Officer, Paul Peter Tak, MD, PhD, FMedSci, and E. Antonio Chiocca, MD, PhD, FAANS, principal investigator for the CAN-3110 clinical trial, will present data and overviews pertaining to the companys oncolytic viral immunotherapies at the 13th International Oncolytic Virus Conference.
  • Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies.
  • Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer

Retrieved on: 
Tuesday, October 19, 2021
Adult, University, GLOBE, Patient, Industry, Associate, Combination therapy, Clinical trial, Physician, Vanderbilt-Ingram Cancer Center, Form, Private Securities Litigation Reform Act, COVID-19, Large-cell lung carcinoma, Internal medicine, Tumor microenvironment, National, Time, Nasdaq, National Cancer Institute, HSV, SEC, American College, Society, Government, American College of Physicians, Growth, Doctor of Philosophy, American Society of Clinical Oncology, Breast cancer, Crizotinib, Therapy, Brain, Nestin, Cancer, ICP34.5, Trial of the century, Acceleration, CADL, Oncology, University School, Vanderbilt University, Pancreatic cancer, Immunogenic cell death, Neoplasm, Herpes simplex virus, Company, Pharmaceutical industry, Vaccine

I am delighted to welcomeMaceas an advisor to Candel Therapeuticsto further strengthen ourteam, said Dr.Tak.

Key Points: 
  • I am delighted to welcomeMaceas an advisor to Candel Therapeuticsto further strengthen ourteam, said Dr.Tak.
  • Prior to joining Candel, Dr. Rothenberg served as Chief Medical Officer of Pfizer.
  • He also served as an Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio and Executive Officer of the Southwest Oncology Group.
  • Candel is at the forefront of one of the most exciting approaches in cancer immunotherapy, said Dr. Rothenberg.

Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Retrieved on: 
Monday, October 4, 2021
HSV, Therapy, Clinical trial, Neoplasm, Pancreatic cancer, Herpes simplex virus, Private Securities Litigation Reform Act, Immunogenic cell death, Cancer, Patient, Annual general meeting, Adult, Form, Company, Immunotherapy, Large-cell lung carcinoma, CADL, CD8, Nestin, Trial of the century, Brain, Combination therapy, Tumor microenvironment, Nasdaq, SITC, SEC, Society, GLOBE, Pharmaceutical industry, Vaccine

Details from the presentation will be available on the Candel website at https://www.candeltx.com/news/ .

Key Points: 
  • Details from the presentation will be available on the Candel website at https://www.candeltx.com/news/ .
  • Nestinishighlyexpressed in high-grade glioma cellsand other tumor tissues, but it is absent in healthy adult brain.
  • Encouraging clinical results of the ongoing phase 1 clinical trial were recently presented at the 2021 American Society of Clinical Oncology Annual Meeting.
  • Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.